[Special Stock] Theragen Etex Secures Technology for Virus Vaccines Including COVID-19... Pursues Commercialization with CDMO Companies

[Asia Economy Reporter Hyunseok Yoo] Teragen Etex is showing strong performance. The news that its wholly-owned subsidiary Teragen Bio has obtained a patent for an immune epitope prediction algorithm, a core technology for developing vaccines against COVID-19 and other emerging infectious diseases, appears to have influenced the stock price.

As of 10:13 AM on the 9th, Teragen Etex was trading at 8,660 KRW, up 6.26% (510 KRW) compared to the previous trading day.

A representative from Teragen Bio stated, "We have obtained a patent for an immune epitope prediction method and computer program for virus treatment," and introduced it as "an artificial intelligence (AI) technology that predicts nucleotide sequence regions optimized for immune formation in the body by analyzing immunogenicity and binding affinity based on viral genome data."

The representative explained, "With this patented technology, vaccine models for various viruses can be designed," and added, "We are reviewing commercialization through the use of our own genome analysis technology and partnerships with domestic and international contract development and manufacturing organizations (CDMOs)."

They also added, "Our focus is on responding to newly emerging infectious diseases in the future."

Teragen Bio possesses a viral genome RNA analysis system using NGS (Next-Generation Sequencing). Through this patent, it has simultaneously secured its own sequencing capability and AI-based infectious disease vaccine development capability.

This content was produced with the assistance of AI translation services.